Photodynamic therapy (PDT) employs a photosensitizing agent that preferentially accumulates, at least to some degree, in malignant tissues and the tumor vasculature. The photosensitizer (PS) is then activated
Bremachlorin® is a second-generation photosensitizer that is currently undergoing careful scientific evaluation in the Netherlands. The agent is known as Radachlorin® in Russia, where it is clinically approved